View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 12, 2021

ICR says immunotherapy cocktail could be effective for head cancers

A combination of nivolumab plus ipilimumab could become a substitute for ‘extreme’ chemotherapy for head and neck cancer patients.

The Institute of Cancer Research (ICR) in London has reported that a combination of immunotherapies could be effective as first-line therapy for relapsed or metastatic head and neck cancer patients in a Phase III CheckMate 651 clinical trial.

The cocktail of immunotherapies, nivolumab and ipilimumab, is created to induce the immune system to fight cancer.

Against traditional ‘extreme’ chemotherapy, the immunotherapy treatment led to longer survival in some advanced head and neck cancer patients.

Standard ‘extreme’ treatment comprises an aggressive combination of two chemotherapy drugs and targeted antibody therapy.

Funded by Bristol Myers Squibb, the Phase III trial enrolled a total of 947 subjects.

The results from the Phase III trial were not statistically significant but were clinically meaningful, ICR said.

Furthermore, a positive trend in survival was observed in subjects receiving the immunotherapy combination versus ‘extreme’ standard treatment in programmed death-ligand 1(PD-L1)-expressing tumour patients.

Survival rates in subjects with increased levels of PD-L1, receiving the immunotherapy combination, were the highest ever recorded in a first-line treatment trial for relapsed or metastatic head and neck cancer, the institute added.

Even though the survival benefit failed to attain statistical significance, subjects on immunotherapy treatment had lesser side effects, signifying the potential to boost the quality of life of the patients.

The Institute of Cancer Research, London chief executive professor Kristian Helin said: “Immunotherapies are kinder, smarter treatments that can bring significant benefits to patients with advanced head and neck cancer, for example, by sparing them some of the difficult side effects of chemotherapy.

“These are promising results and demonstrate how we can better select the patients who are most likely to benefit from immunotherapy treatment.”

Another trial, CheckMate 141, led by ICR and The Royal Marsden researchers had demonstrated the efficiency of nivolumab alone in head and neck cancer.

Based on this data, the US Food and Drug Administration and the European Medicines Agency granted approval for the immunotherapy in 2016.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena